MN-166

DRUG6 trials

Sponsors

MediciNova, Mayo Clinic

Conditions

ALSAmyotrophic Lateral SclerosisGBMGlioblastomaHealthy VolunteersNewly Diagnosed GlioblastomaRecurrent Glioblastoma

Phase 1

Study of MN-166 (Ibudilast) Extended Release Tablet Formulations Compared With Capsules in Healthy Volunteers

CompletedNCT03533387

MediciNovaHealthy Volunteers

Start: 2018-04-11End: 2018-09-30Updated: 2019-05-31

Study to Evaluate Ibudilast and TMZ Combo Treatment in Newly Diagnosed and Recurrent Glioblastoma

CompletedNCT03782415

MediciNovaGBM, Glioblastoma, Newly Diagnosed Glioblastoma +1

Start: 2018-12-29End: 2023-08-07Updated: 2025-05-21

Relative Bioavailability of MN-166 (Ibudilast) in Extended Release Tablet vs. Intermediate-release Capsule in Healthy Volunteers

CompletedNCT04054206

MediciNovaHealthy Volunteers

Start: 2019-06-24End: 2020-05-31Updated: 2020-07-15

Phase 2

Ibudilast (MN-166) in Subjects With Amyotrophic Lateral Sclerosis (ALS)

CompletedNCT02238626

MediciNovaAmyotrophic Lateral Sclerosis

Start: 2014-09-30End: 2017-12-31Updated: 2021-11-05

Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS

Active, not recruitingNCT04057898

MediciNovaAmyotrophic Lateral Sclerosis

Start: 2020-05-28End: 2028-04-01Updated: 2026-03-06

Unknown Phase

Scalable Expanded Access With Analysis of Neurofilament and Other Biomarkers for Ibudilast in ALS

Updated: 2026-08-18

Related Papers

Phase 1b/2a study evaluating the combination of MN-166 (ibudilast) and temozolomide in patients with newly diagnosed and recurrent glioblastoma (GBM).

Journal of Clinical Oncology2024-06-013 citations

Targeting patient recovery priorities in degenerative cervical myelopathy: design and rationale for the RECEDE-Myelopathy trial—study protocol

BMJ Open2023-03-0110 citations

COMBAT-ALS Phase 2b/3 Trial of MN-166 (Ibudilast) in ALS: Study Design and Trial Update (5149)

Neurology2020-04-142 citations